Arthur Allen, Gregory Piazza, Margaret Fang/LinkedIn
Sep 12, 2025, 15:44
Long-Term Apixaban Use for Provoked VTE: Focus on HI-PRO Trial by Arthur Allen, Margaret Fang and Gregory Piazza
Anticoagulation Forum shared on LinkedIn:
”Join us for our free October webinar: Emerging Evidence: Long-term oral anticoagulation following provoked VTE? A focus on the HI-PRO Trial
Tuesday, October 7, 2025 | 12:00 PM ET
Join us as expert faculty review findings from the recent HI-PRO Trial on the use of apixaban for extended treatment of provoked venous thromboembolism (VTE).
What you’ll learn:
- Key insights from trial design and results
- Clinical implications for real-world practice
- Patient selection considerations for extended therapy
Faculty:
Arthur Allen, PharmD, CACP – Salt Lake City Va Health Care System
Margaret Fang, MD, MPH – University of California, San Francisco
Gregory Piazza, MD, MS – Brigham and Women’s Hospital”
Register here.
Stay informed on all webinars and seminars in the field of thrombosis with Hemostasis Today.
-
Oct 28, 2025, 14:27Maha Othman on 10-Year Anniversary of the CanVECTOR Research Network!
-
Oct 28, 2025, 14:00Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
-
Oct 28, 2025, 13:31Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
-
Oct 28, 2025, 12:28Courtney Lawrence: Honored to Team Up with BET on Blood at AABB 2025
-
Oct 27, 2025, 19:45Benedikt Lorenz on Liver Failure and Coagulation – Myths, Traps, and Bad Habits
-
Oct 28, 2025, 13:09Gregory Piazza on CORONA-VTE Network Analysis
-
Oct 27, 2025, 18:42Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
-
Oct 27, 2025, 13:30Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 15:10David McIntosh Reflects on International Plasma Awareness Week
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
Oct 28, 2025, 14:27
Oct 28, 2025, 13:09
Oct 28, 2025, 12:28
Oct 27, 2025, 15:10
Oct 27, 2025, 14:33
Oct 27, 2025, 13:30
Oct 27, 2025, 13:18
Oct 27, 2025, 13:00